AGING, September 2014, Vol. 6 No. 9
Abstract: This report describes a novel, comprehensive, and personalized therapeutic program that is based on the
underlying pathogenesis of Alzheimer’s disease, and which involves multiple modalities designed to achieve metabolic
enhancement for neurodegeneration (MEND). The first 10 patients who have utilized this program include patients with memory loss associated with Alzheimer’s disease (AD), amnestic mild cognitive impairment (aMCI), or subjective cognitive impairment (SCI). Nine of the 10 displayed subjective or objective improvement in cognition beginning within 3‐6 months, with the one failure being a patient with very late stage AD. Six of the patients had had to discontinue working or were struggling with their jobs at the time of presentation, and all were able to return to work or continue working with improved performance. Improvements have been sustained, and at this time the longest patient follow‐up is two and one‐half years from initial treatment, with sustained and marked improvement. These results suggest that a larger, more extensive trial of this therapeutic program is warranted.
The results also suggest that, at least early in the course, cognitive decline may be driven in large part by metabolic processes. Furthermore, given the failure of monotherapeutics in AD to date, the results raise the possibility that such a therapeutic system may be useful as a platform on which drugs that would fail as monotherapeutics may succeed as key components of a therapeutic system.
AGING, June 2016, Vol. 8 No. 6
Abstract: Alzheimer’s disease is one of the most significant healthcare problems nationally and globally. Recently, the
first description of the reversal of cognitive decline in patients with early Alzheimer’s disease or its precursors, MCI (mild
cognitive impairment) and SCI (subjective cognitive impairment), was published . The therapeutic approach used was
programmatic and personalized rather than monotherapeutic and invariant, and was dubbed metabolic enhancement for
neurodegeneration (MEND). Patients who had had to discontinue work were able to return to work, and those struggling
at work were able to improve their performance. The patients, their spouses, and their co‐workers all reported clear
improvements. Here we report the results from quantitative MRI and neuropsychological testing in ten patients with
cognitive decline, nine ApoE4+ (five homozygous and four heterozygous) and one ApoE4‐, who were treated with the
MEND protocol for 5‐24 months.
The magnitude of the improvement is unprecedented, providing additional objective evidence that this programmatic approach to cognitive decline is highly effective. These results have far‐reaching implications for the treatment of Alzheimer’s disease, MCI, and SCI; for personalized programs that may enhance pharmaceutical efficacy; and for personal identification of ApoE genotype.
Journal of Alzheimers Disease & Parkinsonism, October 2018, Vol. 8 Issue 5
Abstract: The first examples of reversal of cognitive decline in Alzheimer’s disease and the pre-Alzheimer’s disease conditions MCI (Mild Cognitive Impairment) and SCI (Subjective Cognitive Impairment) have recently been published. These two publications described a total of 19 patients showing sustained subjective and objective improvement in cognition, using a comprehensive, precision medicine approach that involves determining the potential contributors to the cognitive decline (e.g., activation of the innate immune system by pathogens or intestinal permeability, reduction in trophic or hormonal support, specific toxin exposure, or other contributors), using a computer-based algorithm to determine subtype and then addressing each contributor using a personalized, targeted, multi-factorial approach dubbed ReCODE for reversal of cognitive decline. An obvious criticism of the initial studies is the small number of patients reported. Therefore, we report here 100 patients, treated by several different physicians, with documented improvement in cognition, in some cases with documentation of improvement in electrophysiology or imaging, as well. This additional report provides further support for a randomized, controlled clinical trial of the protocol and the overall approach.
Dale E. Bredesen, MD
The instant New York Times and Wall Street Journal bestseller.
A groundbreaking plan to prevent and reverse Alzheimer’s Disease that fundamentally changes how we understand cognitive decline.
Everyone knows someone who has survived cancer, but until now no one knows anyone who has survived Alzheimer's Disease.
In this paradigm shifting book, Dale Bredesen, MD, offers real hope to anyone looking to prevent and even reverse Alzheimer's Disease and cognitive decline. Revealing that AD is not one condition, as it is currently treated, but three, The End of Alzheimer’s outlines 36 metabolic factors (micronutrients, hormone levels, sleep) that can trigger "downsizing" in the brain. The protocol shows us how to rebalance these factors using lifestyle modifications like taking B12, eliminating gluten, or improving oral hygiene.
The results are impressive. Of the first ten patients on the protocol, nine displayed significant improvement with 3-6 months; since then the protocol has yielded similar results with hundreds more. Now, The End of Alzheimer’s brings new hope to a broad audience of patients, caregivers, physicians, and treatment centers with a fascinating look inside the science and a complete step-by-step plan that fundamentally changes how we treat and even think about AD.
Aired on 11/3/2016
The Bredesen Program, a groundbreaking new treatment, is showing signs of reversing the symptoms of Alzheimer's disease. California neurologist Dale Bredesen says the program is designed to fix imbalances in the body, but warns that it is not a cure. NBC special anchor Maria Shriver reports in the latest edition of our Brain Power TODAY series.